Incyte Q3 2026 Earnings Call: Revenue Up 14%, Sales Guidance Raised
Source Tradingkey
Key Takeaways
- Incyte reported Q3 2026 total revenue of $1.56 billion, up 14% year over year, while total net sales rose 14% to $1.32 billion.
- Jakafi franchise net sales increased 4% to $827 million, supported by 12% underlying demand growth. Jakafi XR generated $15 million.
- Opzelura net sales grew 36% to $255 million. On a pro forma basis excluding the prior-year Medicaid line-extension settlement benefit, sales increased 21%.
- Core business net sales excluding Jakafi reached $490 million, up 30%, driven by Opzelura, Niktimvo, Zynyz and Monjuvi.
- Management raised 2026 guidance for Opzelura, Hematology and Oncology, and total net sales. The new total net sales outlook is $5.2 billion to $5.3 billion.
- GAAP expenses rose 146% to $2.27 billion, primarily because of a $1.23 billion acquired in-process R&D charge associated with the Vega Therapeutics acquisition.
Core Financial Data
| Metric | Q3 2026 | Year-over-year change | Commentary |
|---|---|---|---|
| Total revenue | $1.56 billion | +14% | Broad-based product growth |
| Total net sales | $1.32 billion | +14% | Driven by strong product demand |
| Jakafi franchise net sales | $827 million | +4% | Underlying demand increased 12% |
| Jakafi XR net sales | $15 million | — | XR represented approximately 3% of the franchise in September |
| Core net sales excluding Jakafi | $490 million | +30% | Led by Opzelura, Niktimvo, Zynyz and Monjuvi |
| Opzelura net sales | $255 million | +36% | Pro forma growth was 21% |
| GAAP operating expenses | $2.27 billion | +146% | Included $1.23 billion of Vega-related acquired IPR&D |
| GAAP R&D expenses | $1.79 billion | +254% | Increased 11% excluding the Vega acquisition |
| GAAP SG&A expenses | $364 million | +11% | Included povorcitinib pre-launch spending |
| Cash and cash equivalents | $3.9 billion | — | Quarter-end balance |
Business and Operating Performance
Disclaimer: The content available on Mitrade Insights is provided for informational and marketing purposes only. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Recommended Articles
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookThe financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
The financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
Understand how the Strait of Hormuz shock moved markets, and what CFD traders watched next.
Ripple (XRP) and Stellar (XLM) are showing signs of recovery on Tuesday after rebounding slightly the previous day, following double-digit corrections last week.
WTI Price Forecast: Climbs above $86.00 as 100-day SMA breakout comes into playWest Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
West Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
Gold price (XAU/USD) holds steady near $4,335 after pulling back from an early-June top near $4,450 during the early Asian trading hours on Wednesday.
